ArticleScientific reports2026
Pilot deployment of beta carotene-enriched rice (Golden Rice) in the Philippines.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Golden Rice, registered as Malusog Rice in the Philippines, is a biofortified rice containing beta carotene in its grains to address vitamin A deficiency (VAD), a prevalent public health problem. It can provide 30-50% of the estimated average requirement for vitamin A. Its commercial approval in July 2021 led to a pilot-scale deployment in selected high VAD prevalent areas. From 2022 wet cropping season to 2023 wet cropping season, it was cultivated on 202 hectares across 24 provinces in the country, demonstrating significant field performance comparable to that of other rice varieties. It gained an average yield of 3.9t/ha and a maximum yield of 8.3t/ha. Over 77 tons of Malusog Rice were distributed to its target VAD beneficiaries, while eight tons were allocated for market testing. Survey results show that 97% of the target VAD beneficiaries expressed their desire to include Malusog Rice in their diet when it becomes widely available. Moreover, market testing indicates that Malusog Rice was found to be a marketable product, with a price comparable to regular/well-milled rice. The milestone approval and deployment of Malusog Rice in the Philippines position the country as a global leader in agricultural biotechnology, being the first to approve and deploy genetically engineered rice with nutritional benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.